Csl Ltd has released a press release.
AFSTYLA (rFVIII-Single Chain) European Commission Approval
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- Positive Results from CSL112 Phase 2b Trial
- Afstyla CHMP Recommendation
- FDA Accepts BLA for Hereditary Angioedema Therapy
- 2016 FY Results Announcements and Analysts Briefing
- AFSTYLA (rFVIII-Single Chain) FDA approval
Later from CSL
- FY2017 Profit Upgrade
- Half Year Results Analysts Presentation
- Half Year Results Release
- CSL to Acquire Majority Stake in Chinese Plasma Fractionator
- FDA approves CSL Berhings HAEGARDA
Follow CSL into a list and get an email when it puts out news.
Follow CSL